S2. Peptide Hormones, Growth Factors, Related Substances And Mimetics
All prohibited substances in this class are non-Specified Substances.
The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:
S2.1. Erythropoietins (epo) And Agents Affecting Erythropoiesis, Including, But Not Limited To:
S2.1.1 Erythropoietin-receptor Agonists, E.g.
- Darbepoetins (dEPO)
- Erythropoietins (EPO)
- EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]
- EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide)
S2.1.2 Hypoxia-inducible Factor (hif) Activating Agents, E.g.
- Cobalt
- Daprodustat (GSK1278863)
- IOX2
- Molidustat (BAY 85-3934)
- Roxadustat (FG-4592)
- Vadadustat (AKB-6548)
- Xenon
S2.1.3 Gata Inhibitors, E.g.
- K-11706
S2.1.4 Transforming Growth Factor -beta (tgf-Β) Signaling Inhibitors, E.g.
- Luspatercept
- Sotatercept
S2.1.5 Innate Repair Receptor Agonists, E.g.
- Asialo EPO
- Carbamylated EPO (CEPO)
S2.2. Peptide Hormones And Their Releasing Factors
S2.2.1 testosterone-stimulating Peptides In Males Including, But Not Limited To:
- chorionic gonadotrophin (CG)
- luteinizing hormone (LH)
- gonadotrophin- releasing hormone (GnRH, gonadorelin) and its
agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin,
nafarelin and triptorelin) - kisspeptin and its agonist analogues
S2.2.2 Corticotrophins And Their Releasing Factors, E.g. Corticorelin And Tetracosactide
S2.2.3 Growth Hormone (gh), Its Analogues And Fragments, Including, But Not Limited To:
- growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon
- growth hormone fragments, e.g. AOD-9604 and hGH 176-191
S2.2.4 Growth Hormone Releasing Factors, Including, But Not Limited To:
- growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)
- growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin]
- GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6]
S2.3. Growth Factors And Growth Factor Modulators
Including, but not limited to:
- Fibroblast growth factors (FGFs)
- Hepatocyte growth factor (HGF)
- Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues
- Mechano growth factors (MGFs)
- Platelet-derived growth factor (PDGF)
- Thymosin-β4 and its derivatives e.g. TB-500
- Vascular endothelial growth factor (VEGF)
and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
